Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRKCG Antibody | Login | PRKCG Antibody | ||||||||||||||||
|
||||||||||||||||||
| STAT2 Antibody | Login | STAT2 Antibody | ||||||||||||||||
|
||||||||||||||||||
| STAT4 Antibody (Phospho-Tyr693) | Login | STAT4 Antibody (Phospho-Tyr693) | ||||||||||||||||
|
||||||||||||||||||
| PRKCQ Antibody | Login | PRKCQ Antibody | ||||||||||||||||
|
||||||||||||||||||
| PRKCZ Antibody (Phospho-Thr410) | Login | PRKCZ Antibody (Phospho-Thr410) | ||||||||||||||||
|
||||||||||||||||||
| STAT5A Antibody (Phospho-Ser780) | Login | STAT5A Antibody (Phospho-Ser780) | ||||||||||||||||
|
||||||||||||||||||
| STAT5A Antibody (Phospho-Tyr694/699) | Login | STAT5A Antibody (Phospho-Tyr694/699) | ||||||||||||||||
|
||||||||||||||||||
| STAT5A Antibody - middle region | Login | STAT5A Antibody - middle region | ||||||||||||||||
|
||||||||||||||||||
| STAT5A Antibody | Login | STAT5A Antibody | ||||||||||||||||
|
||||||||||||||||||
| STAT5B Antibody | Login | STAT5B Antibody | ||||||||||||||||
|
||||||||||||||||||
| PSEN1 Antibody | Login | PSEN1 Antibody | ||||||||||||||||
|
||||||||||||||||||
| PXN Antibody (Phospho-Tyr88) | Login | PXN Antibody (Phospho-Tyr88) | ||||||||||||||||
|
||||||||||||||||||
| SMC1A Antibody (Phospho-Ser966) | Login | SMC1A Antibody (Phospho-Ser966) | ||||||||||||||||
|
||||||||||||||||||
| PXN Antibody (Phospho-Tyr118) | Login | PXN Antibody (Phospho-Tyr118) | ||||||||||||||||
|
||||||||||||||||||
| SIGLEC5 Antibody - middle region | Login | SIGLEC5 Antibody - middle region | ||||||||||||||||
|
||||||||||||||||||
| HDAC3 Antibody - C-terminal region | Login | HDAC3 Antibody - C-terminal region | ||||||||||||||||
|
||||||||||||||||||
| MAPKAPK5 Antibody (Phospho-Thr182) | Login | MAPKAPK5 Antibody (Phospho-Thr182) | ||||||||||||||||
|
||||||||||||||||||
| ESPL1 Antibody (Phospho-Ser801) | Login | ESPL1 Antibody (Phospho-Ser801) | ||||||||||||||||
|
||||||||||||||||||
| ESPL1 Antibody | Login | ESPL1 Antibody | ||||||||||||||||
|
||||||||||||||||||
| CBFB Antibody - N-terminal region | Login | CBFB Antibody - N-terminal region | ||||||||||||||||
|
||||||||||||||||||
| KAT2B Antibody - C-terminal region | Login | KAT2B Antibody - C-terminal region | ||||||||||||||||
|
||||||||||||||||||
| EIF2AK3 Antibody (Phospho-Thr981) | Login | EIF2AK3 Antibody (Phospho-Thr981) | ||||||||||||||||
|
||||||||||||||||||
| PTGES Antibody - middle region | Login | PTGES Antibody - middle region | ||||||||||||||||
|
||||||||||||||||||
| TP53I3 Antibody - C-terminal region | Login | TP53I3 Antibody - C-terminal region | ||||||||||||||||
|
||||||||||||||||||
| TGFB1 ELISA Kit (Rabbit) | Login | TGFB1 ELISA Kit (Rabbit) | ||||||||||||||||
|
||||||||||||||||||


